Budget Amount *help |
¥19,110,000 (Direct Cost: ¥14,700,000、Indirect Cost: ¥4,410,000)
Fiscal Year 2014: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2013: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2012: ¥13,260,000 (Direct Cost: ¥10,200,000、Indirect Cost: ¥3,060,000)
|
Outline of Final Research Achievements |
Tumor endothelial cells (TEC) from mouse xenografted tumor, especially that from highly metastatic tumor expresses high level of biglycan. Knock down of biglycan by siRNA suppressed tumor cell invasion thorough endothelial cell sheet. Co-implantation of low metastatic tumor cells with TEC developed lung metastases. This metastatic ability was abandoned by suppression of biglycan expression in TEC. Immunohistochemistry of human clinical tumors revealed specific expression of biglycan in TEC. ELISA of serum showed high biglycan level in cancer patients, especially those with metastasis.
|